[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Tharimmune director Thomas Clay Kahler filed an initial Form 3 reporting ownership of a derivative security: a stock option to buy 50,000 shares of Tharimmune common stock (ticker THAR) with an exercise price of $1.33. The option has an expiration date of 08/04/2035; 25,000 shares vested on grant and 25,000 vest on 08/04/2026. The Form 3 indicates the filing was made by one reporting person.

Insights

Corporate Governance Expert

TL;DR: Routine insider initial ownership disclosure of options by a company director; standard vesting schedule disclosed.

This Form 3 is a standard initial Section 16 filing showing a director-level option grant rather than open-market purchases or transfers. The grant size (50,000 options) and exercise price ($1.33) are stated, with half vesting immediately and half vesting one year later. For governance review, this confirms timely disclosure of equity compensation but contains no additional material events such as related-party transactions or unusual acceleration terms.

Securities Compliance Analyst

TL;DR: Compliance disclosure appears complete for an initial beneficial-ownership report; no discrepancies visible in the filing text.

The filing identifies the reporting person, address, relationship to issuer (Director), event date (04/28/2025), and option mechanics (exercise price, underlying shares, expiration). The signature block is present with a signature date of 08/22/2025. From a compliance standpoint, this is a routine public record of equity compensation under Section 16 requirements and does not by itself implicate trading violations.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kahler Thomas Clay

(Last) (First) (Middle)

C/O THARIMMUNE, INC.

34 SHREWSBURY AVE., SUITE 1C

(Street)

RED BANK NJ 07701

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/28/2025

3. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	08/04/2035	Common Stock	50,000	$1.33	D

Explanation of Responses:

1. 25,000 of the options vest on date of grant and 25,000 vest on August 4, 2026.

	/s/ Thomas Clay Kahler	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Thomas Clay Kahler report on his Form 3 for THAR?

The Form 3 reports a stock option for 50,000 shares of Tharimmune common stock at an exercise price of $1.33, expiring on 08/04/2035.

How does the option vest according to the Form 3?

According to the filing, 25,000 options vested on the date of grant and 25,000 vest on 08/04/2026.

What is Thomas Kahler's relationship to Tharimmune as stated on the Form 3?

The filing lists Thomas Clay Kahler as a Director of Tharimmune, Inc.

When was the event requiring this Form 3 reported?

The Date of Event Requiring Statement is listed as 04/28/2025.

When was the Form 3 signed?

The signature block shows the Form was signed by Thomas Clay Kahler on 08/22/2025.